Collectively, the atypical binding profiles in human prostate cancer cells presented for many well-characterized CBR ligands relative to those predicted for canonical CBRs provide additional support for our initial binding screens (Figure 1), suggesting that the CBRs expressed in the cancer cell lines examined here are indeed non-canonical. This evidence concerns the gene CNR1 and prostate cancer.